Industry & Policy News

[Cancer Research UK] Cancer Research UK and France’s Institut National Du Cancer announced a new scientific partnership to help fund world-class researchers to take on cancer’s toughest challenges through the global Cancer Grand Challenges initiative.

[ARPA-H] ARPANET-H is a nationwide health innovation network that connects people, innovators, and institutions. This network is anchored by three regional hubs.

[Oncolytics Biotech Inc.] The $5 million grant will enable Oncolytics to continue the next stage of its research focused on a clinical trial with Oncolytics' proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy, with or without an immune checkpoint inhibitor.

[Fierce Biotech] The German biotech is partnering with the Center for Epidemic Preparedness Innovations, accepting up to $90 million from the foundation as part of a broader pandemic preparation initiative.

[Nature] Women who don’t menstruate — including postmenopausal women and those on contraceptives — were several times more likely to experience unexpected vaginal bleeding after COVID-19 vaccination than before the vaccines were offered, a study finds.

[LAPIX Therapeutics, Inc.] APIX Therapeutics, Inc. announced that it has received clearance of its Investigational New Drug (IND) application from the US FDA to initiate a Phase I clinical trial for its first-in-class, immune tolerance restoration small molecule, LPX-TI641, for the treatment of multiple sclerosis.